Marshall Wace’s Mirum Pharmaceuticals MIRM Stock Holding History

Marshall Wace’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,650	Closed	-$430K	–	3517
2026 Q1	$430K	Sell	4,650 -98,053	-95%	-$9.22M	﹤0.01%	2510
2025 Q4	$8.11M	Buy	102,703 +62,871	+158%	+$4.51M	0.01%	949
2025 Q3	$2.92M	Buy	39,832 +14,295	+56%	+$909K	﹤0.01%	1432
2025 Q2	$1.3M	Buy	+25,537	New	+$1.14M	﹤0.01%	1747
2025 Q1	–	Sell	-175,913	Closed	-$7.27M	–	2906
2024 Q4	$7.27M	Buy	175,913 +152,191	+642%	+$6.34M	0.01%	912
2024 Q3	$925K	Buy	23,722 +3,202	+16%	+$128K	﹤0.01%	1678
2024 Q2	$702K	Buy	20,520 +5,420	+36%	+$142K	﹤0.01%	1824
2024 Q1	$379K	Buy	+15,100	New	+$415K	﹤0.01%	2033
2022 Q3	–	Sell	-10,960	Closed	-$214K	–	3626
2022 Q2	$214K	Buy	+10,960	New	+$259K	﹤0.01%	3150
2022 Q1	–	Sell	-52,527	Closed	-$839K	–	3744
2021 Q4	$839K	Sell	52,527 -16,982	-24%	-$264K	﹤0.01%	2554
2021 Q3	$1.38M	Buy	+69,509	New	+$1.13M	0.01%	1799

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's MIRM Position: Q2 2026 in Review

Marshall Wace sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 4,650 shares — an estimated $430K sold.

Marshall Wace first reported a position in MIRM in Q3 2021 and held it in 11 quarters. The position peaked at $8.11M in Q4 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Marshall Wace reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 4,650 Mirum Pharmaceuticals shares in Q2 2026, an estimated $430K.
Marshall Wace first reported a position in Mirum Pharmaceuticals in Q3 2021 and held it in 11 quarters.
Marshall Wace's Mirum Pharmaceuticals position peaked at $8.11M in Q4 2025.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.